Fmr LLC Cuts Stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
FMR LLC reduced its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 29.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,965,768 shares of the biotechnology company’s stock after selling 816,679 shares during the period. FMR LLC’s holdings in Atara Biotherapeutics were worth $40,397,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Atara Biotherapeutics during the first quarter valued at approximately $132,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Atara Biotherapeutics during the first quarter worth $185,000. American International Group Inc. increased its stake in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in shares of Atara Biotherapeutics by 62.6% in the first quarter. Parametric Portfolio Associates LLC now owns 25,389 shares of the biotechnology company’s stock worth $522,000 after buying an additional 9,774 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. bought a new stake in shares of Atara Biotherapeutics during the first quarter worth $555,000. Institutional investors and hedge funds own 81.59% of the company’s stock.
Shares of Atara Biotherapeutics, Inc. (ATRA) traded up 2.68% on Friday, reaching $15.30. The company had a trading volume of 165,039 shares. Atara Biotherapeutics, Inc. has a 52 week low of $11.80 and a 52 week high of $25.73. The firm’s market capitalization is $445.37 million. The company’s 50-day moving average price is $14.69 and its 200 day moving average price is $15.88.
TRADEMARK VIOLATION NOTICE: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/04/atara-biotherapeutics-inc-nasdaqatra-shares-sold-by-fmr-llc-updated-updated-updated.html.
ATRA has been the topic of a number of recent research reports. Canaccord Genuity reaffirmed a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a research report on Friday, April 21st. Zacks Investment Research downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. Jefferies Group LLC reissued a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a report on Thursday, June 22nd. William Blair reissued an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. Finally, ValuEngine downgraded Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $25.75.
In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 5,500 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $16.49, for a total value of $90,695.00. Following the transaction, the chief executive officer now owns 731,859 shares of the company’s stock, valued at $12,068,354.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Christopher Haqq sold 6,000 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $12.65, for a total value of $75,900.00. Following the completion of the transaction, the executive vice president now directly owns 368,080 shares in the company, valued at approximately $4,656,212. The disclosure for this sale can be found here. Insiders sold 54,308 shares of company stock worth $797,382 in the last ninety days. 16.10% of the stock is owned by corporate insiders.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.